Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. (NYSE: NUVB) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its oncology business, financial position and key agreements. On this page, you can review NUVB’s current reports on Form 8‑K and other SEC filings alongside AI-generated summaries that help explain the significance of each document.
For Nuvation Bio, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources for information on its pipeline of targeted cancer therapies, including taletrectinib (IBTROZI) for ROS1-positive non-small cell lung cancer, safusidenib for IDH1-mutant gliomas, NUV-868 and its drug-drug conjugate platform. These filings typically describe clinical programs such as the TRUST registrational studies for taletrectinib and the G203 study for safusidenib, as well as risk factors relevant to oncology drug development and commercialization.
Nuvation Bio also uses Form 8‑K to disclose material events. Recent 8‑K filings have reported preliminary financial results and net product revenue for IBTROZI, the entry into a license and collaboration agreement with Eisai Co., Ltd. for taletrectinib in multiple territories, publication of positive Phase 2 data for safusidenib, and strategic decisions such as discontinuation of NUV-1511 while continuing the underlying DDC platform. Other 8‑Ks have furnished earnings press releases and updated corporate presentations.
Investors interested in equity structure and trading can consult registration statements and periodic reports for details on Nuvation Bio’s Class A common stock and redeemable warrants, which trade on the New York Stock Exchange under the symbols NUVB and NUVB.WS. Form 4 insider transaction reports, when available, can be used to track purchases and sales of NUVB securities by directors and officers.
Stock Titan enhances access to these filings with AI-powered summaries that highlight key terms in complex agreements, explain financial disclosures in plain language and point out important milestones, such as collaboration payments or changes in clinical program status. Real-time updates from EDGAR ensure that new NUVB filings appear promptly, while structured views of 10‑K, 10‑Q, 8‑K and Form 4 documents help users quickly locate the information most relevant to their analysis of Nuvation Bio’s oncology business.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised options and sold shares in a planned transaction. On April 17, 2026, Wentworth exercised options to acquire 36,750 shares of Class A common stock at $2.93 per share, then sold 36,750 shares in open-market trades at a weighted-average price of $5.0144 under a Rule 10b5-1 trading plan. After these transactions, Wentworth directly owns 53,000 shares of Nuvation Bio Class A common stock.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised options and sold shares in a planned transaction. On April 17, 2026, Wentworth exercised options to acquire 36,750 shares of Class A common stock at $2.93 per share, then sold 36,750 shares in open-market trades at a weighted-average price of $5.0144 under a Rule 10b5-1 trading plan. After these transactions, Wentworth directly owns 53,000 shares of Nuvation Bio Class A common stock.
Nuvation Bio Inc. chief medical officer Dongfang Liu reported an exercise-and-sell transaction in Class A common stock. Liu exercised stock options to acquire 50,000 shares at $1.94 per share, then sold 50,000 shares in open-market trades at a weighted-average price of $5.02 per share.
The sales, executed at prices ranging from $5.00 to $5.07, were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Liu holds 18,000 shares of Class A common stock and 430,000 stock options expiring on February 27, 2033.
Nuvation Bio Inc. chief medical officer Dongfang Liu reported an exercise-and-sell transaction in Class A common stock. Liu exercised stock options to acquire 50,000 shares at $1.94 per share, then sold 50,000 shares in open-market trades at a weighted-average price of $5.02 per share.
The sales, executed at prices ranging from $5.00 to $5.07, were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Liu holds 18,000 shares of Class A common stock and 430,000 stock options expiring on February 27, 2033.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting a proposed sale of 36,750 shares of Common Stock via the exercise of stock options on 04/17/2026.
The filing also records that 200,000 shares were sold under a 10b5-1 plan on 04/06/2026 by Kerry Wentworth for $903,550.
Nuvation Bio Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 21, 2026. The meeting will be held via live audio webcast at www.virtualshareholdermeeting.com/NUVB2026, with a record date of March 25, 2026.
Stockholders will vote on electing three directors to serve until the 2029 annual meeting, ratifying KPMG LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers. Holders of 346,685,831 Class A shares and 1,000,000 Class B shares are entitled to one vote per share.
The board is classified into three classes with seven total members and has determined that six directors, including the lead independent director, are independent under NYSE standards. Non-employee directors generally receive cash retainers plus annual stock option grants, while executive pay combines salary, annual performance-based bonuses and equity awards.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised stock options for a total of 200,000 shares of Class A Common Stock on April 6, 2026, at exercise prices of $1.87 and $1.94 per share. The same day, Wentworth sold 200,000 shares in open-market transactions at a weighted-average price of $4.5178 per share, with individual sale prices ranging from $4.44 to $4.64, pursuant to a pre-arranged Rule 10b5-1 trading plan. After these transactions, Wentworth directly holds 53,000 shares of Class A Common Stock.
Nuvation Bio Inc. reported that its Chief Medical Officer, Dongfang Liu, received a grant of stock options covering 748,130 shares of common stock. The award is classified as a grant or other acquisition rather than an open-market purchase.
According to the terms, the option vests as to 25% of the underlying shares on the one-year anniversary of February 27, 2026, with the remaining portion vesting in equal monthly installments over the following 36 months. Vesting is conditioned on Dr. Liu’s continuous service with the company on each applicable vesting date.
Nuvation Bio Inc. reported that officer Makunje Moses received new equity awards. On February 27, 2026, Moses was granted stock options for 224,439 shares at an exercise price of $0.00 per share and 50,761 shares of Class A Common Stock as restricted stock units (RSUs).
The stock option vests 25% on the one-year anniversary of February 27, 2026, then monthly over the next 36 months, contingent on continued service. The RSUs vest in four equal annual installments on the issuer’s quarterly vesting date following each of the first four anniversaries from February 27, 2026, also conditioned on continued service.